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The Brain Tumor Center, Department of Neurosurgery, The University of Chicago, Chicago, IL 60637, USAGrade IV astrocytoma, termed glioblastoma multiforme (GBM) is death receptor (DR) expression on the surface of glioblastoma cells,
one themost aggressive malignancies known to man. Despite intensive
therapies, themedian survival has remained approximately 15months.
One of themajor challenges to the treatment of CNSmalignancies is the
blood brain barrier (BBB). The barrier is designed to be incredibly selec-
tive, whichmeans few therapeutics given to patients will reliably arrive
at the site of the malignancy. To overcome the BBB and low blood ﬂow
that tends to occur within these tumors, various biodegradable mate-
rials, polymers and nanoparticles that can slowly release therapeutics
at the site of the tumor have been developed. In the past, various che-
motherapies have been attempted to be delivered in this way (Kane
et al., 2015). The major problem with direct treatment of tumors is the
low amount of diffusion and inefﬁcient delivery of therapeutics. There
have been attempts at enhanced delivery using convection based ther-
apies, which until this point have not generated signiﬁcant survival ad-
vantage in patients. Furthermore, the diffuse nature of the tumormeans
it may spread far from the treatment site. It is for these reasons that a
carrier with a high amount of versatility and tumor-homing capability
is urgently needed.
Beginningwith a critical discovery in 2000, it was demonstrated that
neural stem cells (NSCs) have intrinsic glioma-tropic properties, even to
distant sites (Aboody et al., 2000). Since this initial ﬁnding, NSCs have
been manipulated in a number of ways to elicit anti-cancer effects.
First, NSCs can be engineered to produce different genes. In a pioneering
preclinical study, Dr. Aboody's laboratory generated an NSC cell line
carrying cytosine deaminase (CD). After systemic treatment with the
pro-drug Gancyclovir (GCV), the suicide gene converts the GCV into its
toxic di (and tri) phosphate form only where the NSCs have migrated.
This has provided signiﬁcant efﬁcacy in a pre-clinical model of GBM
while preventing off-target toxicity (Aboody et al., 2013). A phase I
clinical trial utilizing this approach has recently completed accrual
(Clinical Trial Identiﬁer—NCT02015819). Other groups have generated
NSC cell lines with other anti-cancer agents. NSCs expressing the
anti-tumor molecule TRAIL (tumor necrosis factor-related apoptosis-
inducing ligand) have recently come back into focus after groups have
been able to sensitize glioblastoma cells to TRAIL using a number of
novel compounds such as the cardiac glycoside lanatoside C and the his-
tone deacetylase inhibitor MS-275 (Teng et al., 2014; Bagci-onder et al.,
2013). Both therapies are thought to function by inﬂuencing alternative⁎ Corresponding author.
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Other than directlymodifying the NSC, these cells can also be loaded
with therapeutic cargo. Our group had previously loaded NSC with
mesoporous nanoparticles containing doxorubicin, attached via a pH
sensitive linker (Cheng et al., 2013). This targeted release of chemother-
apeutics had signiﬁcant impact on animal survival in a mouse model of
glioma. Other nanoparticles have also been successfully loaded into
NSC, for example another group loaded gold nanorods (AuNR) onto
NSC carriers, which enhanced the distribution of the nanoparticles to
the tumor tissue (Mooney et al., 2014). After treatment with near-
infrared radiation, the gold nanoparticles convert light to tumor-
killing heat, which therapeutic effect covers a signiﬁcantly larger
area than injection of particles alone.
The use of NSC carriers has recently been extended into the loading
of adenoviruses. By allowing either the infection or replication only
within cancer cells, the use of recently developed conditionally targeted
or replicative adenoviruses (CRAds) has become an attractive modality
for treatment. This allows for a “1–2 punch” of both oncolysis and
enhanced delivery of therapeutics, while also minimizing off-target
toxicity. By loading a conditionally replicative adenovirus (CRAd-
Survivin-pk7) onto NSC carriers, we have demonstrated enhanced
anti-tumor efﬁcacy compared to viral treatment alone (Ahmed et al.,
2013). Previous studies have been performed to suggest this modality
of CRAd delivery is efﬁcacious and is currently planned for a phase-I
clinical trial.
The route of delivery of NSCs is critical for an efﬁcacious therapy,
because the amount of NSCs that can make it to the glioma tissue is
highly dependent on their route of administration. In murine models
of GBM, injection of NSCs contralateral to the tumor site causes their
migration and efﬁcient delivery of therapy (Ahmed et al., 2013). The
problem in human patients is that intratumoral injections are invasive
and troublesome for repeat injections. While intravenous administration
of NSCs can still cause migration to the tumor site, the efﬁcacy of this
route remains controversial. Recently, as away to curtail these limitations,
it has been demonstrated that NSC can be delivered intra-nasally and
efﬁciently migrate to the tumor tissues. The intranasal route allows for
repeat administration and has higher amounts of NSC migration
(Schmidt et al., 2014).
These methods of direct treatment to the tumor have advanced
signiﬁcantly from simply administering drugs directly to the tumor
site. Stem cells and the therapies they carry provide a powerful new
platform for treating malignancies. The ﬁeld of cellular carriers is stillthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
775J. Miska, M.S. Lesniak / EBioMedicine 2 (2015) 774–775in its infancy, and there are still many obstacles to overcome for this
therapy to become successful. It is important to note that the loading
of adenoviruses into NSCs enhances survival in amurinemodel of glioma
much better than virus loaded mesenchymal stem cells (MSC), both of
which are tumor tropic carriers (Ahmed et al., 2011). This suggests that
the trafﬁcking efﬁcacy of carriers might be closely linked to the similarity
between the origin of the carrier and the malignancy. Substantial work
needs to be done in understandingwhat causes different types of carriers
to migrate to tissues differentially. With the results of some early clinical
trials on the horizon, wewill get a clearer picture of how efﬁcacious NSCs
are as carriers of therapeutics. Through the development of both
increasingly speciﬁc therapeutics and better delivery systems, there is
a hope that we will see dramatic enhancements in patient outcomes
for this terrible disease.
Conﬂict of Interest
The authors declare no conﬂicts of interest.
References
Aboody, K.S., Brown, A., Rainov, N.G., Bower, K.A., Liu, S., Yang, W., Small, J.E., Herrlinger,
U., Ourednik, V., Black, P.M., Breakeﬁeld, X.O., Snyder, E.Y., 2000. Neural stem cells
display extensive tropism for pathology in adult brain: evidence from intracranial
gliomas. Proc. Natl. Acad. Sci. U. S. A. 97, 12846–12851.Aboody, K.S., Najbauer, J., Metz, M.Z., D'Apuzzo, M., Gutova, M., Annala, A.J., Synold, T.W.,
Couture, L.A., Blanchard, S., Moats, R.A., Garcia, E., Aramburo, S., Valenzuela, V.V.,
Frank, R.T., Barish, N.E., Brown, C.E., Kim, S.U., Badie, B., Portnow, J., 2013. Neural
stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Science
Translational Medicine 5, 184ra59.
Ahmed, A.U., Tyler, M.A., Thaci, B., Alexiades, N.G., Han, Y., Ulasov, I.V., Lesniak, M.S., 2011.
A comparative study of neural and mesenchymal stem cell-based carriers for
oncolytic adenovirus in a model of malignant glioma. Mol. Pharm. 8, 1559–1572.
Ahmed, A.U., Thaci, B., Tobias, A.L., Aufﬁnger, B., Zhang, L., Cheng, Y., Kim, C.K., Yunis, C., Han,
Y., Alexiades, N.G., Fan, X., Aboody, K.S., Lesniak, M.S., 2013. A preclinical evaluation of
neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
J. Natl. Cancer Inst. 105, 968–977.
Bagci-onder, T., Agarwal, A., Flusberg, D., Wanningen, S., Sorger, P., Shah, K., 2013. Real-time
imaging of the dynamics of death receptors and therapeutics that overcome trail
resistance in tumors. Oncogene 32, 2818–2827.
Cheng, Y., Morshed, R., Cheng, S.H., Tobias, A., Aufﬁnger, B., Wainwright, D.A., Zhang, L.,
Yunis, C., Han, Y., Chen, C.T., Lo, L.W., Aboody, K.S., Ahmed, A.U., Lesniak, M.S., 2013.
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma
targeting and therapy. Small 9, 4123–4129.
Kane, J.R., Miska, J., Young, J.S., Kanojia, D., Kim, J.W., Lesniak, M.S., 2015. Sui generis: gene
therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol. 17
Suppl. 2, ii24–ii36.
Mooney, R., Roma, L., Zhao, D.H., Van Haute, D., Garcia, E., Kim, S.U., Annala, A.J., Aboody, K.S.,
Berlin, J.M., 2014. Neural stem cell-mediated intratumoral delivery of gold nanorods
improves photothermal therapy. ACS Nano 8, 12450–12460.
Schmidt, N.O., Duhrsen, L., Reitz, M., Henze, M., Sedlacik, J., Riecken, K., Fehse, B., Westphal,
M., 2014. Repeated intranasal application of neural stem cell-mediated enzym/prodrug
therapy using a novel Hsv-thymidine kinase variant improves therapeutic efﬁciency in
an intracranial glioblastoma model. Neuro-Oncology 16.
TENG, J., HEJAZI, S., BADR, C.E., TANNOUS, B.A., 2014. Systemic anticancer neural stem
cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells
32, 2021–2032.
